These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 18296863

  • 1. Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.
    Hirata T, Funatsu T, Keto Y, Akuzawa S, Sasamata M, Miyata K.
    J Pharmacol Sci; 2008 Feb; 106(2):264-70. PubMed ID: 18296863
    [Abstract] [Full Text] [Related]

  • 2. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):190-5. PubMed ID: 17658508
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
    Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M.
    Inflammopharmacology; 2007 Feb 14; 15(1):5-9. PubMed ID: 17323187
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
    Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M.
    J Pharmacol Sci; 2007 Jul 14; 104(3):263-73. PubMed ID: 17652911
    [Abstract] [Full Text] [Related]

  • 5. Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.
    Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K.
    Eur J Pharmacol; 2008 Jun 10; 587(1-3):281-4. PubMed ID: 18456254
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation.
    Miyata K, Ito H, Yamano M, Hidaka K, Kamato T, Nishida A, Yuki H.
    Eur J Pharmacol; 1993 Dec 07; 250(2):303-10. PubMed ID: 8112388
    [Abstract] [Full Text] [Related]

  • 7. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer.
    Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K.
    Neurogastroenterol Motil; 2008 May 07; 20(5):557-65. PubMed ID: 18221252
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effect of the selective serotonin 5-HT₃ receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats.
    Nakata-Fukuda M, Hirata T, Keto Y, Yamano M, Yokoyama T, Uchiyama Y.
    Eur J Pharmacol; 2014 May 15; 731():88-92. PubMed ID: 24632457
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effect of ramosetron on corticotropin releasing factor- and soybean oil-induced delays in gastric emptying in rats.
    Hirata T, Keto Y, Yamano M, Yokoyama T, Sengoku T, Seki N.
    J Gastroenterol Hepatol; 2012 Sep 15; 27(9):1505-11. PubMed ID: 22554268
    [Abstract] [Full Text] [Related]

  • 10. 5-HT6 receptor antagonism reduces defecation in rat: A potential treatment strategy for irritable bowel syndrome with diarrhea.
    Hagsäter SM, Lisinski A, Eriksson E.
    Eur J Pharmacol; 2019 Dec 01; 864():172718. PubMed ID: 31586629
    [Abstract] [Full Text] [Related]

  • 11. Involvement of the 5-HT3 receptor in CRH-induce defecation in rats.
    Miyata K, Ito H, Fukudo S.
    Am J Physiol; 1998 May 01; 274(5):G827-31. PubMed ID: 9612262
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
    Hirata T, Funatsu T, Keto Y, Akuzawa S, Akiho H, Nishida A, Sasamata M, Miyata K.
    Nihon Yakurigaku Zasshi; 2009 May 01; 133(5):281-91. PubMed ID: 19443966
    [No Abstract] [Full Text] [Related]

  • 13. Effect of zaldaride maleate, an antidiarrheal compound, on fecal pellet output induced by hyperpropulsion in gastrointestine of rats.
    Aikawa N, Ohmori K.
    Jpn J Pharmacol; 2000 Apr 01; 82(4):350-2. PubMed ID: 10875756
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological evaluation of a novel corticotropin-releasing factor 1 receptor antagonist T-3047928 in stress-induced animal models in a comparison with alosetron.
    Itomi Y, Tanaka T, Matsushita K, Kawamura T, Kojima T, Aso K, Matsumoto-Okano S, Tsukimi Y.
    Neurogastroenterol Motil; 2020 May 01; 32(5):e13795. PubMed ID: 31970891
    [Abstract] [Full Text] [Related]

  • 15. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q, Zhang Y, Chen F, Zuo X, Li Y.
    BMC Gastroenterol; 2018 Jan 08; 18(1):5. PubMed ID: 29310568
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY, Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, Choi MK, Bak YT, Rhee PL.
    Neurogastroenterol Motil; 2011 Dec 08; 23(12):1098-104. PubMed ID: 21920001
    [Abstract] [Full Text] [Related]

  • 17. Effect of YNS-15P, a new alpha-2 adrenoceptor antagonist, on stress-stimulated colonic propulsion in rats.
    Yamamoto O, Niida H, Tajima K, Shirouchi Y, Kyotani Y, Ueda F, Kise M, Kimura K.
    J Pharmacol Exp Ther; 1998 Nov 08; 287(2):691-6. PubMed ID: 9808698
    [Abstract] [Full Text] [Related]

  • 18. 5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
    Kishibayashi N, Miwa Y, Hayashi H, Ishii A, Ichikawa S, Nonaka H, Yokoyama T, Suzuki F.
    J Med Chem; 1993 Oct 29; 36(22):3286-92. PubMed ID: 8230119
    [Abstract] [Full Text] [Related]

  • 19. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K.
    Clin Gastroenterol Hepatol; 2014 Jun 29; 12(6):953-9.e4. PubMed ID: 24315882
    [Abstract] [Full Text] [Related]

  • 20. Effect of the 5-hydroxytryptamine3 (5-HT3)-receptor antagonist KB-R6933 on experimental diarrhea models.
    Ozaki A, Yoshidomi M, Sukamoto T.
    Jpn J Pharmacol; 1999 May 29; 80(1):93-6. PubMed ID: 10446763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.